CytoDyn, Inc. (CYDY)
0.2502
0.00 (0.00%)
USD |
OTCM |
Nov 16, 16:00
CytoDyn Enterprise Value : 374.79M for Nov. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 16, 2026 | 374.79M |
| November 13, 2026 | 370.14M |
| November 12, 2026 | 358.36M |
| November 11, 2026 | 348.18M |
| November 10, 2026 | 356.76M |
| November 09, 2026 | 355.23M |
| November 06, 2026 | 345.12M |
| November 05, 2026 | 339.54M |
| November 04, 2026 | 343.23M |
| November 03, 2026 | 340.03M |
| November 02, 2026 | 331.01M |
| October 30, 2026 | 330.87M |
| October 29, 2026 | 338.14M |
| October 28, 2026 | 319.23M |
| October 27, 2026 | 327.52M |
| October 26, 2026 | 358.86M |
| October 23, 2026 | 389.04M |
| October 22, 2026 | 359.81M |
| October 21, 2026 | 367.37M |
| October 20, 2026 | 374.64M |
| October 19, 2026 | 374.50M |
| October 16, 2026 | 342.87M |
| October 15, 2026 | 309.60M |
| October 14, 2026 | 301.78M |
| October 13, 2026 | 300.15M |
| Date | Value |
|---|---|
| October 12, 2026 | 301.78M |
| October 09, 2026 | 301.78M |
| October 08, 2026 | 303.96M |
| October 07, 2026 | 301.64M |
| October 06, 2026 | 301.78M |
| October 05, 2026 | 301.78M |
| October 02, 2026 | 301.78M |
| October 01, 2026 | 300.33M |
| September 30, 2026 | 309.05M |
| September 29, 2026 | 304.69M |
| September 28, 2026 | 325.81M |
| September 25, 2026 | 341.05M |
| September 24, 2026 | 320.75M |
| September 23, 2026 | 313.42M |
| September 22, 2026 | 309.78M |
| September 21, 2026 | 327.31M |
| September 18, 2026 | 321.74M |
| September 17, 2026 | 316.33M |
| September 16, 2026 | 307.60M |
| September 15, 2026 | 302.80M |
| September 14, 2026 | 298.58M |
| September 11, 2026 | 298.22M |
| September 10, 2026 | 287.24M |
| September 09, 2026 | 301.49M |
| September 08, 2026 | 300.50M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.321B |
| Alnylam Pharmaceuticals, Inc. | 20.79B |
| Anika Therapeutics, Inc. | 154.24M |
| Savara, Inc. | 818.43M |
| Arrowhead Pharmaceuticals, Inc. | 6.454B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -19.94M |
| Total Expenses (Quarterly) | 19.94M |
| EPS Diluted (Quarterly) | -0.0147 |
| Earnings Yield | -17.71% |
| Normalized Earnings Yield | -11.31 |